New class of agents for treatment of hypertension: focus on direct renin inhibition by Fogari, Roberto & Zoppi, Annalisa
© 2010 Fogari and Zoppi, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2010:6 869–882
Vascular Health and Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
869
ReView
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/VHRM.S4189
New class of agents for treatment  
of hypertension: focus on direct renin inhibition
Roberto Fogari
Annalisa Zoppi
Department of internal Medicine and 
Therapeutics, University of Pavia, italy
Correspondence: Roberto Fogari
Clinica Medica ii Dipartimento di 
Medicina interna, Piazza Golgi 19, 27100 
Pavia, italy
Tel +39 038 252 6217
Fax +39 038 252 6259
email r.fogari@unipv.it
Abstract: Aliskiren, the first orally active direct renin inhibitor, is an effective antihypertensive 
drug with distinctive characteristics, including good blockade of the renin-angiotensin system, a 
prolonged duration of action, pharmacologic effects that persist after drug discontinuation, and 
favorable tolerability comparable with placebo. The blood pressure-lowering effect of aliskiren 
monotherapy is similar, if not superior, to that of other first-line antihypertensive agents, and is 
greatly enhanced when aliskiren is combined with various other antihypertensive medications, 
without any adverse drug interactions. Aliskiren is also an effective and well tolerated therapy 
in special populations, including diabetic, obese, and elderly hypertensives. Beyond its blood 
pressure-lowering efficacy, results from experimental and clinical trials suggest that aliskiren 
has positive effects on markers of cardiovascular and renal damage. The ASPIRE (Aliskiren 
Study in Post-MI patients to Reduce rEmodelling) HIGHER clinical trials program is further 
assessing whether the promising pharmacologic properties of aliskiren translate into reduced 
risk of adverse cardiovascular and renal outcomes.
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Introduction
The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in the homeo-
static regulation of blood pressure (BP), fluid electrolytic balance, tissue perfusion, and 
vascular growth.1 Renin catalyzes the cleavage of angiotensinogen, producing the deca-
peptide, angiotensin I (Ang I). Angiotensin-converting enzyme (ACE) then catalyzes the 
conversion of Ang I to the octapeptide Ang II, the primary effector of the RAAS. The 
binding of Ang II to its Type 1 receptors, besides mediating its main biologic effects, 
including vasoconstriction, cell proliferation, hypertrophy, and aldosterone secretion, 
provides feedback inhibition of further renin release by the kidney (Figure 1). Additional 
components of the RAAS have been identified in the last decade, including bioactive 
Ang peptides, such as Ang III, Ang IV , and Ang-(1-7), the effects of which have not yet 
been fully elucidated for the cardiovascular and renal system.2 The discovery of the renin 
receptor has shed further light on the biology of the RAAS. Renin, simply considered 
until recently as the rate-limiting enzyme of RAAS activation, has also turned out to be 
the ligand for a protein known as the renin/prorenin receptor (RPR), which binds renin 
and prorenin about equally, regardless of their biologic activities.3 Prorenin, which rep-
resents 70%–90% of total circulating renin, when bound to the RPR, induces an increase 
in the catalytic efficiency of angiotensinogen conversion to Ang I, which contributes to 
local production of Ang II and its systemic levels, as well as binding of renin/prorenin Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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to the RPR, exerting physiologic effects that are independent 
of Ang II, including activation of intracellular signal pathways, 
enhanced synthesis of DNA, and stimulation of the release of 
plasminogen activator inhibitor (PAI-1), collagen-1, fibronec-
tin, and transforming growth factor beta-1.3
Pharmacologic blockade of the RAAS has proven to be 
an effective therapeutic strategy in the treatment of several 
cardiovascular disorders, including hypertension, heart fail-
ure, renal disease, and atherosclerosis.4 Until now, in clinical 
practice, the drug classes that provided RAAS inhibition 
included ACE inhibitors (ACEIs), which block the conversion 
of Ang I to Ang II, angiotensin receptor blockers (ARBs), 
which interfere with Ang II binding to its Type 1 receptors, 
and aldosterone antagonists, which inhibit aldosterone action 
via the mineralocorticoid receptor (MR) receptor. However, 
suppression of RAAS remains incomplete with these agents, 
due to the disruption of the negative feedback effect of Ang II 
on renin release, with a consequent increase in plasma renin 
activity (PRA) and reactive activation of the RAAS.5 More-
over, the increased Ang I levels seen with ACEIs can lead 
to “escape”, because Ang I is converted to Ang II by non-
ACE pathways, mediated by chimase and chymotrypsin-like 
angiotensin-generating enzyme. Increased levels of Ang I and 
II could also lead to increased levels of biologically active 
Ang fragments.2 Therefore, direct renin inhibition may be a 
more optimal pharmacologic approach to RAAS inhibition 
by interrupting the system at its first regulated step.6
The purpose of this review is to update the different 
aspects of the antihypertensive potential of aliskiren, the 
first direct renin inhibitor available for clinical use. We will 
also discuss the role of aliskiren in the protection of target 
organs and the prevention of cardiovascular morbidity and 
mortality.
Direct renin inhibitors and aliskiren
The chemical development of renin inhibitors can be 
divided into three generations of compounds.7 First, there 
were the peptide analogs of angiotensinogen which block 
the enzymatic action of renin, second, the peptidomimetic 
agents that are dipeptide transition-state analog inhibitors of 
the active site, and third, the nonpeptide-like compounds, 
of which aliskiren is the most successful example.8 The 
first- and second-generation compounds were limited by 
poor metabolic stability and oral bioavailability, weak BP-
lowering efficacy, short duration of action, and high cost of 
synthesis. The third-generation compounds benefited from 
advances in crystallography and a structure-based approach 
to drug design, which led to the development of aliskiren.7,9 
Molecular modeling was used to design and modify the 
aliskiren molecule, the structure of which was based on 
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x-ray crystallographic analysis of the active site of renin.8 
Aliskiren interacts with several binding pockets in distinct 
regions around the active site of renin, in particular, the renin 
subpocket (S3sp).8 Compared with peptidomimetic renin 
inhibitors, aliskiren has lower lipophilicity, which renders it 
more resistant to intestinal degradation. The hepatic extrac-
tion ratio (12%) indicates a low rate of first-pass metabolism 
and the resulting bioavailability (about 2.6%) is significantly 
greater than that of the earlier renin inhibitors. After admin-
istration of a single 150 mg or 300 mg dose of the drug, 
peak plasma concentration is reached within 2.5–3.0 hours, 
while steady-state plasma concentrations are reached within 
7–8 days.10 About 90% of the absorbed dose of aliskiren is 
eliminated by the fecal route and less than 0.6% is recovered 
in the urine. The terminal half-life ranges between 23 and 
40 hours, which makes it suitable for once-daily dosing. 
Pharmacokinetic studies have shown that there is no need 
for dose adjustment in patients with renal or hepatic disease 
or for elderly patients or patients with diabetes.11,12 Due to 
its lack of effect on cytochrome P450 isoenzyme activities, 
aliskiren has a low potential for drug interactions.9
Effects of aliskiren on RAS 
components
The different approach to renin-angiotensin system (RAS) 
blockade of aliskiren as compared with ACEIs and ARBs 
results in differing effects on RAAS components (Table 1). 
In clinical studies using aliskiren, a significant reduction of 
PRA ranging from 70% to 75% was observed. This contrasts 
with both ACEIs and ARBs, which increase PRA due to 
disruption of the negative feedback loop whereby Ang II sup-
presses renin release and stimulates a reactive rise in plasma 
renin concentrations (PRC). Aliskiren increases renin release 
by the same mechanisms and augments PRC. However, 
the enzymatic activity of the renin released is blocked by 
aliskiren and PRA is reduced. Concerns have been expressed 
about the high aliskiren-induced reactive increase in plasma 
renin and prorenin, because even though aliskiren may lack 
enzymatic activity, it can still bind to the RPR, a signaling 
pathway of as yet unknown significance.13 An important 
question is whether aliskiren inhibits the enzymatic effects 
of renin/prorenin when they are bound to the RPR. Available 
information suggests that it does. Although the drug does not 
block direct intracellular effects, Feldman et al reported that 
aliskiren downregulates RPR expression in diabetic transgenic 
rats.14 In humans we have no direct evidence of this. However, 
there are no data from clinical trials done in 14,000 patients to 
indicate that the rise in PRC in any way limits the ability of 
aliskiren to inhibit PRA or lower BP. Besides, even if more 
renin is released in response to aliskiren than with RAAS 
blockers, there is no evidence that this overcomes the enzy-
matic inhibition of renin. Given that all RAAS blockers, as 
well as other antihypertensive drugs, including diuretics and 
calcium channel blockers (CCBs), increase PRC levels yet 
have proved effective in reducing long-term cardiovascular 
endpoints, it seems unlikely that increases in PRC resulting 
from aliskiren administration could act as an agonist at the 
RPR with potentially deleterious consequences.15 Further-
more, recent literature also indicates that large increase in 
PRC levels with aliskiren may be in part artifactual, because 
commercial PRC assays overestimate the renin concentration 
in plasma samples containing a direct renin inhibitor.16
Aliskiren in hypertension
Clinical trials involving more than 14,000 patients have 
shown that aliskiren, alone or in combination with other 
antihypertensive agents, provides effective BP reduction 
with a good safety and tolerability profile.
Monotherapy
The first demonstration of the antihypertensive efficacy of 
aliskiren monotherapy was seen in 2001 in a group of mild 
to moderate hypertensives treated with aliskiren 75 mg or 
150 mg for two weeks.17 Clinic and ambulatory BP values 
were significantly reduced by aliskiren without important 
adverse events. Following this success, a dose-finding study 
was conducted in 226 patients with mild to moderate hyper-
tension who were randomly assigned to receive aliskiren 
37.5 mg, 75 mg, 150 mg, or 300 mg, or losartan 100 mg 
once daily for four weeks.18 Dose-dependent reductions in 
BP were observed, and the best 24-hour effect of aliskiren 
on ambulatory BP was demonstrated for the 300 mg dose. 
Table 1 Changes in renin, plasma renin activity, plasma Ang i, 
plasma Ang ii and tissue Ang ii levels in response to antihypertensive 
drug classes affecting various sites of the RAAS
Drug class Renin PRA Plasma 
Ang I
Plasma 
Ang II
Tissue 
Ang II
ACe i ↑↑ ↑↑ ↑↑ =↓ =↓
ARB ↑↑ ↑↑ ↑↑ ↑↑ ↑↑
Diuretics ↑↑ ↑ ↑ ↑ ↑
Renin inhibitor ↑↑ ↓↓ ↓↓ ↓↓ ?
ARB + Renin inhibitor ↑↑↑↑ ↓ = = ?
Abbreviations:↑,  increase;  ↓,  decreased;  =,  unchanged;  ACe  i,  angiotensin 
converting enzyme inhibitors; ARB, angiotensin type i receptor blocker; DRi, direct 
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After these two preliminary studies, the antihypertensive 
efficacy of aliskiren monotherapy has been further assessed 
in comparison with placebo and with other antihypertensive 
drugs.
Comparisons with placebo
In 2005, a placebo-controlled study was conducted in 518 
hypertensive patients who were randomized to treatment 
with aliskiren at daily doses of 150 mg, 300 mg, and 600 mg, 
or placebo, for eight weeks.19 All the aliskiren doses pro-
duced a significant reduction of BP compared with placebo, 
but the plateau of the dose-response curve was reached at 
300 mg, and little or no additional BP reduction occurred 
with the 600 mg dose. Another study versus placebo 
involved   540   Japanese hypertensives, who were treated 
with aliskiren 75 mg, 150 mg, and 300 mg once daily for 
eight weeks. Aliskiren was consistently superior to placebo 
in lowering BP, but again a significant dose-response effect 
was observed when aliskiren was increased from 150 mg/
day to 300 mg/day.20
The largest study of aliskiren versus placebo was per-
formed by Oh et al21 who evaluated the effects of 150 mg, 
300 mg, and 600 mg of aliskiren in 672 patients for eight 
weeks, confirming the efficacy and the dose-response effect 
of the drug. In a subgroup of 216 patients who underwent 
ambulatory BP monitoring, the antihypertensive effect of 
aliskiren was sustained throughout the 24-hour dosing period, 
was similar during the day-time and night-time periods, and 
was maintained towards the end of the dosing period. The 
trough:peak ratios were 0.64 and 0.98 for the 150 mg and 
300 mg dosages, respectively, which confirmed the long 
duration of action of aliskiren. The drug also provided smooth 
24-hour BP control, as demonstrated by the mean smoothness 
index, which was 0.64 for the 150 mg dose and 0.60 for the 
300 mg dose, compared with 0.17 for placebo.
The study by Oh et al was the first to demonstrate a 
persistent BP reduction effect after aliskiren withdrawal, an 
advantage that has been confirmed by other studies.22,23 In 
a controlled withdrawal study, patients who had received 
aliskiren for 11 months were randomized to continue treat-
ment with aliskiren or placebo. After four weeks, BP values 
in the aliskiren-treated patients did not return to baseline, 
and PRA remained suppressed by about 50%.22 Likewise, 
the results of an ambulatory BP monitoring study, designed 
to evaluate the antihypertensive efficacy of aliskiren follow-
ing simulated nonadherence (missed dosing), demonstrated 
that aliskiren 300 mg provided sustained BP-lowering 
effects beyond 24 hours that were longer-lasting than with 
irbesartan 300 mg or ramipril (Figure 2).23 About 91% of 
the systolic BP-lowering effect of aliskiren was maintained 
in the 24 hours after a missed dose as compared with 73% 
for irbesartan and 64% for losartan. A sustained reduction 
in PRA following one or two missed doses (ie, for at least 
72 hours after aliskiren dosing) was also observed. The long 
duration of action of aliskiren in part depends on its long 
elimination half-life and potent renin inhibition. Because 
even patients who are otherwise persistent with taking their 
antihypertensive therapy have been demonstrated to miss a 
dose of treatment occasionally, antihypertensive treatment 
that allows sustained BP-lowering effect beyond the 24-hour 
dosing interval may help to limit the effects of occasional 
poor adherence on BP control.
Comparisons with other antihypertensive 
agents
Diuretics
In a 2006 study, aliskiren 75–300 mg daily was consistently 
more effective than hydrochlorothiazide (HCTZ) 6.25 mg, 
12.5 mg, and 25 mg at reducing BP in hypertensive patients.24. 
The superiority of aliskiren was more evident at higher 
dosages. Another direct comparison study involving 1124 
hypertensive patients confirmed that treatment with aliskiren 
150 mg force-titrated to 300 mg daily reduced systolic/dia-
stolic BP values by a significantly greater amount than HCTZ 
12.5 mg/day titrated to 25 mg/day (−20.3/14.2 mmHg versus 
−18.6/13.0 mmHg, P , 0.05).25 Responder and BP control 
rates were also higher among aliskiren-treated patients.
ACe inhibitors
Three large studies have compared aliskiren with ramipril. 
The first study included 837 hypertensive patients with dia-
betes treated either with aliskiren 150 mg, ramipril 5 mg, 
or aliskiren 150 mg in combination with ramipril 5 mg.26 
After four weeks, dosages were titrated to aliskiren 300 mg, 
ramipril 10 mg, and aliskiren 300 mg + ramipril 10 mg for 
a further four weeks. After eight weeks, aliskiren mono-
therapy produced a greater reduction in systolic BP compared 
with ramipril alone (14.7 versus 12.0 mmHg, P , 0.05) 
and resulted in higher responder rates (73% versus 66%, 
P , 0.05). Interestingly, the incidence of cough was lower 
among patients receiving aliskiren (2.1%) than among those 
receiving ramipril (4.7%). Similar results were obtained in 
nondiabetic hypertensive patients.27 Specifically, 12 weeks of 
treatment with aliskiren 150–300 mg daily resulted in greater Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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reductions in both systolic BP (−14.0 versus −11.3 mmHg, 
P = 0.0027) and diastolic BP (−11.3 versus −9.7 mmHg, 
P = 0.05) compared with ramipril 5–10 mg. Another 
demonstration of the greater antihypertensive efficacy of 
aliskiren compared with ramipril has been provided by the 
AGELESS (Aliskiren for Geriatric LowEring of SyStolic 
Hypertension) study,28 that compared these two drugs in 901 
elderly patients ($56 years) with isolated systolic hyperten-
sion over 36 weeks of treatment. At 12 weeks, aliskiren 
monotherapy 150 mg or 300 mg produced significantly 
greater BP reduction than ramipril 5 mg or 10 mg (−14.0/5.1 
versus −11.6/3.6 mmHg, P = 0.0241 for systolic BP and 
P = 0.0037 for diastolic BP). Furthermore, after 36 weeks, 
aliskiren-based therapy (with optional addition of HCTZ 
12.5 mg or 25 mg and amlodipine 5 mg or 10 mg) lowered BP 
more than ramipril-based therapy (−20.8/8.2 mmHg versus 
−18.1/7.0 mmHg, P = 0.0747 for systolic BP and P , 0.05 
for diastolic BP). In severe hypertension (.180/110 mmHg), 
aliskiren 300 mg and lisinopril 40 mg displayed similar 
antihypertensive efficacy, and the responder and BP control 
rates were similar for the two drugs.29
Angiotensin receptor blockers
After the preliminary study by Stanton17 showing com-
parable antihypertensive efficacy of aliskiren 150 mg 
and 300 mg and losartan 100 mg, Gradman observed that 
irbesartan 150 mg was as effective as aliskiren 150 mg, but 
significantly less effective than aliskiren 300 mg.19 In 2007, 
Oparil et al30 showed that aliskiren 300 mg and valsartan 
320 mg provided similar reductions in both ambulatory and 
clinic BP (−13.0/9.0 mmHg with aliskiren versus −12.8/9.7 
with valsartan). Similar results were also reported by Pool 
et al.31 More recently, the ALLAY (Aliskiren in Left Ven-
tricular Hypertrophy) trial,32 conducted in 465 overweight 
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hypertensives with left ventricular hypertrophy, apart from 
confirming similar BP-lowering efficacy of aliskiren 300 mg 
and losartan 100 mg, also demonstrated that aliskiren was 
as effective as losartan in promoting regression of left 
ventricular mass.
Combination therapy
The majority of patients require two or more antihypertensive 
agents to achieve adequate BP control. Therefore, several 
studies have assessed the effects of aliskiren in combination 
with other antihypertensive drugs.
Aliskiren combined with hydrochlorothiazide
In a large factorial design study, the combination of aliskiren 
75–300 mg with HCTZ 6.25–25 mg produced a significantly 
greater BP decrease than the component monotherapies.24 At 
the highest combined dose of 300/25 mg, BP was reduced 
by a mean of −21.2/14.3 mmHg. A reduced incidence of 
thiazide-induced hypokalemia was also observed with the 
combination, and the HCTZ-induced rise in PRA was neutral-
ized by aliskiren. In another six-month study conducted in 
mild to moderate hypertensives uncontrolled by monotherapy 
with aliskiren or ramipril, addition of HCTZ to aliskiren 
provided significantly greater BP reductions than addition 
of HCTZ to ramipril (−17.9/13.2 versus −15.2/12.0 mmHg, 
P , 0.05).27
Aliskiren combined with amlodipine
Adding aliskiren 150 mg daily to the regimen of hypertensive 
patients who had inadequate BP control with amlodipine 5 mg 
led to greater BP reduction (−11.0/8.5 mmHg) compared with 
continuation of amlodipine 5 mg (−5.0/4.8 mmHg).33 The BP-
lowering effect of the aliskiren-amlodipine combination was 
similar to that of amlodipine 10 mg. Higher responder and 
BP control rates were also observed with the combination 
therapy (64% and 43%, respectively) than with amlodipine 
5 mg alone (45% and 23%). The incidence of ankle edema 
was markedly higher with amlodipine 5 mg or 10 mg (3.4% 
and 11.2%, respectively) than with the aliskiren 150 mg + 
amlodipine 5 mg combination (2.1%).
The effects of addition of aliskiren to amlodipine on ankle 
edema was specifically assessed in a recent study which 
demonstrated that the combination produced a significantly 
less marked increase in both ankle foot volume and pretibial 
subcutaneous tissue pressure (two objective measures of 
ankle edema) than amlodipine alone.34 In addition, the num-
ber of patients with clinically evident peripheral edema was 
lower among patients who received the combination. This 
suggests that direct renin inhibition partially counteracts the 
  microcirculatory changes responsible for CCB-induced edema, 
which is similar to what is observed with ACEIs and ARBs.
The antihypertensive efficacy and tolerability of aliskiren-
amlodipine combination therapy was more recently confirmed 
by a long-term open study involving 556 mild to moderate 
hypertensives.35 At the end of 12 months of treatment with 
aliskiren-amlodipine, a mean decrease of −24.2/15.5 mmHg 
in BP was found, with a rate of BP normalization of 74.3%. 
Interestingly, in this study, the BP-lowering effect was more 
marked in the subgroup of patients with Stage II hyperten-
sion ($160/100 mmHg), who showed a mean BP reduction 
of −29.1/17.1 mmHg, demonstrating that the higher the 
baseline BP level, the greater the antihypertensive efficacy 
of the aliskiren-amlodipine combination.
Aliskiren combined with an ACe inhibitor
The efficacy of adding aliskiren 300 mg to ramipril 10 mg has 
been evaluated in hypertensive patients with diabetes.26 Com-
bination therapy provided a significant additional reduction in 
diastolic BP (−12.8 mmHg) compared with each component 
monotherapy (−10.7 mmHg with ramipril and –11.3 mmHg 
with aliskiren). The combination also produced a greater 
decrease in systolic BP and led to a higher responder rate 
than ramipril monotherapy. Ambulatory BP measurements in 
a subset of 137 patients showed that the addition of aliskiren 
to ramipril resulted in greater reduction of mean 24-hour BP, 
thus improving BP control over 24 hours.36
Aliskiren combined with an ARB
In an eight-week study involving 1797 mild to moderate hyper-
tensive patients, Oparil et al30 reported significantly greater BP 
reductions (−17.2/12.2 mmHg) with an aliskiren 300 mg + 
valsartan 320 mg combination compared with aliskiren alone 
(−13.0/9.0 mmHg) or valsartan alone (−12.8/9.7 mmHg, both 
P , 0.0001 versus the combination). Responder and BP con-
trol rates were also higher among recipients of combination 
therapy (66% and 49%, respectively) than among recipients 
of aliskiren (53% and 37%) and valsartan (55% and 34%) 
monotherapy. An excess of patients developed hyperkalemia 
with the combination, but in most cases this was transient and 
did not require drug discontinuation.
In an ambulatory BP monitoring study, an aliskiren-
  valsartan combination provided a significantly greater decrease 
in 24-hour ambulatory BP than each component monotherapy.37 
The reductions in mean BP were −14.4/10.3 mmHg with the 
combination therapy, −9.8/7.1 mmHg with aliskiren, and 
−10.1/7.1 mmHg with valsartan.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Safety and tolerability
In a pooled analysis that included data from more than 
7000 hypertensive patients, the safety and tolerability profile of 
aliskiren monotherapy at doses of 75–600 mg daily was 
  comparable with that of placebo and ARBs.38 The incidence of 
adverse events in the aliskiren 75 mg (8.6%), 150 mg (7.0%), 
300 mg (9.4%), and 600 mg (11.8%) groups was similar to 
that observed in the placebo group (8.6%). The most com-
mon adverse events were headache (5.7%), nasopharyngitis 
(4.4%), diarrhea (2.6%), dizziness (1.8%), and fatigue 
(1.6%). Cough was substantially less frequent in patients 
treated with aliskiren compared with patients treated with 
ACEIs, and peripheral edema was substantially less frequent 
with aliskiren than with amlodipine. Serious adverse events 
in patients who were treated with aliskiren 75–600 mg were 
rare in the clinical studies, occurring at rates no different 
from placebo (0.3%–06% versus 0.6%).38
The tolerability profile of aliskiren was also good when 
the drug was combined with other antihypertensive medica-
tions. Hypokalemia related to diuretics, CCB-induced periph-
eral edema, and ACEI-related cough were less frequent when 
these drugs were combined with aliskiren. A numerically 
greater proportion of patients developed hyperkalemia when 
aliskiren was combined with ACEIs or ARBs, but this effect 
was transient and not associated with adverse events. Data 
from ASPIRE [Aliskiren Study in Post-MI patients to Reduce 
rEmodelling], recently presented at the American College 
of Cardiology Congress 2010), indicated that, in patients 
receiving aliskiren in addition to standard therapy with an 
ACEI or ARB following myocardial infarction, there was a 
higher rate of hyperkalemia (5.2% versus 1.3%), hypoten-
sion (8.8% versus 4.5%), and kidney dysfunction (2.4% 
versus 0.8%) when compared with patients given standard 
therapy alone.39 These results suggest caution in the use of 
the combination of aliskiren with an RAAS blocker, at least 
in this subset of patients.
Special populations
Diabetic patients
Diabetes is a common comorbidity in hypertensive patients 
and greatly increases the risk of cardiovascular and renal 
disease.40 Aliskiren has exhibited similar pharmacokinetics 
in diabetic patients and healthy volunteers.11 In the already 
cited paper of Uresin et al26 aliskiren 300 mg monotherapy or 
aliskiren 300 mg combined with ramipril 10 mg was demon-
strated to be more effective than ramipril alone in controlling 
BP in hypertensive patients with diabetes, without affecting 
glycemic control.
The antihypertensive efficacy of aliskiren at doses ranging 
from 150 to 300 mg in hypertensive patients with diabetes 
was also demonstrated by a meta-analysis of 10 random-
ized, double-blind studies.41 The mean systolic/diastolic BP 
reductions of −13.2/10.4 mmHg with aliskiren 150 mg and 
of −14.8/12.2 mmHg with aliskiren 300 mg were similar to 
those observed in nondiabetic patients.
Obese patients
Obesity is another common comorbidity in hypertensive 
patients.42 Current hypertension treatment guidelines do not 
provide specific guidance for hypertension in the presence of 
obesity, although its peculiar pathophysiologic characteristics 
(volume expansion, increased cardiac output, and RAS acti-
vation) make thiazide diuretics and RAS inhibitors suitable 
treatment options. In a large multicenter study,43 489 obese 
hypertensives (body mass index $ 30 kg/m²) who were non-
responders to treatment with HCTZ 25 mg were treated with 
aliskiren 150 mg, irbesartan 300 mg, amlodipine 5 mg, or pla-
cebo in addition to HCTZ for four weeks, followed by eight 
weeks of double the initial dose of aliskiren, irbesartan, or 
amlodipine. After eight weeks of treatment, aliskiren-HCTZ 
lowered BP by −15.8/11.9 mmHg, which was significantly 
(P , 0.0001) more than placebo-HCTZ (−8.6/7.9 mmHg) 
and similar to irbesartan-HCTZ (−15.4/11.3 mmHg) and 
amlodipine-HCTZ (−13.6/10.3 mmHg). Combination with 
aliskiren suppressed the increase in PRA caused by HCTZ, 
whereas irbesartan and amlodipine increased PRA further. 
All combinations were well tolerated, although there was a 
higher incidence of ankle edema in the amlodipine-treated 
patients (11.1% versus 0.8% in the aliskiren group and 1.6% 
in the irbesartan group). The authors concluded that aliskiren 
was an effective and well tolerated therapeutic option for 
obese hypertensives who do not respond to first-line thiazide 
diuretic therapy. In a more recent 52-week study involving 
396 obese hypertensives, Schmieder et al44 observed that 
aliskiren-based therapy lowered BP more effectively than 
HCTZ-based therapy (−19.9/15.5 versus −17.5/9.1 mmHg) 
and was associated with a lower incidence of hypokalemia 
(0.8% versus 17.9%, P , 0.0001).
Patients with metabolic syndrome
Metabolic syndrome, a cluster of risk factors that increases 
overall cardiovascular risk, is also common in hypertensive 
patients. In a recent study involving 141 hypertensives 
with metabolic syndrome, aliskiren 300 mg was more 
effective than irbesartan 300 mg in reducing BP values 
(−13.8/7.1 mmHg versus −5.8/2.8 mmHg, P , 0.0001).45 Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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A greater proportion of patients achieved BP control to 
,135/85 mmHg with aliskiren (29.2% versus 16.7%, 
P = 0.019). In another comparative study conducted in 
72 hypertensives with metabolic syndrome, aliskiren 300 mg, 
but not losartan 100 mg, significantly improved insulin 
  sensitivity and fibrinolytic balance.46
elderly patients
Differences in BP control with age have not been observed 
in aliskiren-treated patients. In a double-blind study con-
ducted in 355 elderly hypertensives ($65 years) aliskiren 
at doses ranging from 75 to 300 mg daily was as effective 
as lisinopril 10 mg in lowering 24-hour ambulatory BP 
values.47 The results of the already cited AGELESS study28 
demonstrated that aliskiren was more effective than ramipril 
in reducing BP in elderly patients with systolic hypertension 
and demonstrated a good tolerability profile. In a long-term 
comparative study of an aliskiren-based regimen with a 
HCTZ-based regimen, analysis of BP changes by age group 
showed that aliskiren provided significantly greater reduc-
tions in mean systolic BP (but not diastolic BP) in elderly 
($65 years) and very elderly ($75 years) patients than in 
younger ones.44 Pooled data from seven clinical trials did not 
show a difference in adverse event profile for elderly patients 
compared with younger patients.38
Aliskiren and target organ 
protection
Some studies in animal models have suggested that aliskiren 
has an ability to protect against end organ damage. These 
data are derived mainly from studies of double-transgenic rats 
which express human genes for both renin and angiotensino-
gen. Untreated, these animals develop progressive hyperten-
sion with severe end organ damage and do not survive beyond 
eight weeks of life. When rendered diabetic by streptozotocin, 
they develop progressive renal disease, which is thought to 
be analogous to human diabetic nephropathy.
In humans, the target organ-protective effects of aliskiren 
are being investigated in ASPIRE HIGHER, the largest clini-
cal trials program underway in the cardiorenal disease area, 
involving 14 randomized, double-blind studies including more 
than 35,000 patients with hypertension, diabetes, heart failure, 
renal dysfunction, and previous myocardial infarction.48
Cardiac protection
experimental studies
In a study conducted in double-transgenic rats, aliskiren 
improved systolic and diastolic BP, reduced cardiac 
  hypertrophy, and left ventricular wall thickness, and 
decreased biomarkers of cardiac stress and failure, eg, atrial 
natriuretic peptide.49 Interestingly, in this study, whereas 
100% of animals in the placebo group died by the ninth week 
of the experiment and 26% survived in the valsartan-treated 
group, 100% of the rats survived in the aliskiren-treated 
group. Similar results were obtained by Decherd et al in the 
same animal model.50
In another animal model (mice subjected to cardiac 
ischemia), aliskiren improved left ventricular systolic and 
diastolic function, and reduced cardiac hypertrophy and left 
ventricular dilatation at a dose that did not affect systemic 
BP.51 Furthermore, aliskiren suppressed ischemia-mediated 
activation of inflammation signaling pathways and reduced 
cellular markers of apoptosis.
Clinical studies
Four studies have been conducted in the area of heart failure 
and ventricular remodeling.
In a short-term, open study involving 27 patients, aliskiren 
300 mg was as effective and well tolerated as ramipril 10 mg 
in patients with heart failure.52 Both drugs suppressed RAAS 
activation and reduced levels of B-type natriuretic peptide 
(BNP) to a similar extent (Figure 3).
The most important study that assessed the efficacy 
of aliskiren in patients with heart failure was the ALOFT 
(Aliskiren Observation of Heart Failure Treatment) trial.53 
A total of 302 hypertensives who had stable heart failure 
(New York Heart Association Class II–III) were random-
ized to 12 weeks of treatment with aliskiren 150 mg or 
placebo in addition to prior treatment with an ACEI (or 
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to three months in aliskiren- or placebo-treated chronic heart failure (CHF) patients.   
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ARB) and   beta-blocker. Compared with placebo, aliskiren 
reduced plasma BNP by 25% (P = 0.016), plasma N-terminal 
proBNP by 25% (P = 0.0106) and urinary aldosterone by 21% 
(P = 0.015). An improvement in Doppler echocardiographic 
measurement of left ventricular filling pressure was also 
observed. Aliskiren was well tolerated and there was no 
significant difference between aliskiren and placebo for 
the safety assessment of renal dysfunction, symptomatic 
hypotension, and hyperkalemia. Because reductions in BNP 
and plasma N-terminal proBNP with other RAAS inhibitors 
have been associated with improved cardiovascular outcomes 
in patients with heart failure,54 the neurohormonal results of 
ALOFT suggest that add-on treatment with aliskiren 150 mg 
has the potential to reduce morbidity and mortality in these 
patients.
Left ventricular hypertrophy is a marker of cardiac 
end organ damage and is associated with increased car-
diovascular morbidity and mortality.55 ALLAY (Aliskiren 
in Left Ventricular Hypertrophy) was a 36-week study 
that compared the effects of aliskiren 300 mg and losartan 
100 mg alone and in combination on left ventricular hyper-
trophy (assessed by magnetic resonance imaging) in 465 
  overweight,   hypertensive patients.32 Aliskiren monotherapy 
was   statistically noninferior to losartan in reducing left ven-
tricular mass index (4.9 g/m² for aliskiren versus 4.8 g/m² 
for losartan). The aliskiren-losartan combination resulted in 
a greater reduction in left ventricular mass index (5.8 g/m²) 
compared with losartan monotherapy, although the difference 
was not statistically significant (Figure 4). These results were 
independent of BP decrease. Safety and tolerability were 
similar across all the treatment groups.
ASPIRE evaluated the effects of adding aliskiren to 
standard therapy, including an ACEI or an ARB, on left 
ventricular volume and function after myocardial infarction.39 
A total of 820 post-myocardial infarction patients were ran-
domly treated with aliskiren or placebo in addition to the 
best available medical therapy. At 36 weeks of follow-up, 
echocardiographically assessed left ventricular end-systolic 
volume (the primary outcome) was reduced by an average of 
4.4 mL in the aliskiren group and by 3.5 mL in the placebo 
group (not statistically significant). No between-group differ-
ences were observed in left ventricular end-diastolic volume, 
infarct segment, or the percentage of patients whose ejection 
fraction decreased by more than six points. In addition, the 
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combined rates for cardiovascular deaths, hospitalization 
for heart failure, recurrent heart attack, resuscitated sudden 
death, and stroke were similar between the aliskiren-treated 
patients and those given standard therapy. In contrast, patients 
receiving aliskiren in addition to another RAAS blocker had 
a higher rate of adverse events, particularly hyperkalemia 
and hypotension. The authors concluded that the use of this 
combination was not currently recommended following 
myocardial infarction.
The results of ASPIRE are consistent with those of 
ONTARGET (Ongoing Telmisartan Alone and in combina-
tion with Ramipril Global Endpoint Trial),56 which demon-
strated no additional benefit in primary clinical outcomes 
among patients with vascular disease or high-risk diabetes 
receiving the combination of telmisartan-ramipril than 
outcomes in those treated with ramipril alone. Although 
combination therapy has a greater BP-lowering effect, dual 
RAAS blockade did not produce any significant clinical 
advantage in this high-risk population, but significantly 
increased the risk of hypotension, syncope, renal dysfunc-
tion, and hyperkalemia.
Renal protection
experimental studies
In hypertensive transgenic rats with diabetes, aliskiren was as 
effective as perindopril (an ACEI) in reducing albuminuria, 
fibrosis, and glomerulosclerosis but with a smaller antihy-
pertensive effect, suggesting a more direct and prominent 
renal protective action.57 In the same animal model, Feld-
man et al confirmed the renal protective effect of aliskiren, 
and that aliskiren not only prevents the development of 
albuminuria but also suppresses production of transforming 
growth factor beta, a fibrosis-promoting cytokine.14 In this 
study, autoradiography enabled the investigators to localize 
aliskiren within the kidney and to assess the magnitude of 
renal partitioning. Aliskiren accumulated in renal tissue after 
two weeks of treatment and localized to the glomeruli and to 
the arterial walls of the small cortical blood vessels. These 
findings suggest that suppression of intrarenal RAAS may 
be at least one of the mechanisms contributing to the renal 
protection afforded by aliskiren.
Clinical studies
In a small clinical study58 conducted in 15 hypertensive 
patients with Type 2 diabetes and proteinuria, treatment with 
aliskiren 300 mg daily for four weeks significantly reduced 
the urinary albumin:creatinine ratio as well as 24-hour ambu-
latory BP. The effect of aliskiren on decreasing   albuminuria 
was observed within three days (−17%) and reached a 
  maximal effect (−44%) within 28 days of treatment.
The first large study to assess the renoprotective effects 
of aliskiren was AVOID (Aliskiren in the Evaluation of 
Proteinuria in Diabetes),59 in which 599 patients with diabe-
tes, nephropathy, and proteinuria were treated with losartan 
100 mg followed by the addition of placebo or aliskiren 
300 mg. Adding aliskiren to losartan provided a further 
significant 20% reduction in urinary albumin:creatinine ratio 
compared with the addition of placebo. Almost twice as many 
patients in the aliskiren group achieved a reduction in urinary 
albumin:creatinine ratio of at least 50% from baseline. The 
additive antiproteinuric effect of combining aliskiren with 
losartan appeared to be independent of BP reduction, which 
was similar in the two treatment groups (Figure 5).
In a more recent study, Persson et al60 evaluated the renal 
effects of aliskiren 300 mg or irbesartan 300 mg alone and in 
combination in 26 hypertensive patients with Type 2 diabetes 
and albuminuria. Both monotherapies significantly reduced 
proteinuria, but the reduction was more pronounced with the 
aliskiren-irbesartan combination.
In salt-depleted healthy human subjects, dose-dependent 
increases in renal plasma flow following single-dose treat-
ment with 75 mg, 150 mg, and 300 mg of aliskiren have been 
observed.61 The vasodilator response induced by aliskiren 
was twice that reported with ACEIs, and exceeded the effects 
of ARBs by about 40%. Renal vasodilatation persisted for 48 
hours after a single oral dose. The investigators postulated 
that the effects of aliskiren at the site of the RPR receptor 
may explain the marked renal vasodilator response.
Vascular protection
Experimental and clinical studies have demonstrated that 
RAAS blockade may reduce the development and progression 
of atherosclerotic lesions. For aliskiren, the most informa-
tion comes from experimental studies, whereas few clinical 
data are available.
experimental studies
In rats with renovascular hypertension, aliskiren was shown 
to be as effective as irbesartan in preventing progression of 
atherosclerosis.62 Interestingly, aliskiren increased smooth 
muscle cell content in atherosclerotic plaques significantly 
more than irbesartan, with consequent plaque stabilization. 
Furthermore, in Watanabe heritable hyperlipidemic rabbits, 
treatment with aliskiren significantly increased production 
of intra-aortic acetylcholine-induced nitric oxide, a surro-
gate index of endothelial protective function, and decreased Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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endothelial function. These protective effects were attributed 
to the reduction of cardiac p22(phox)-related nicotinamide 
adenine dinucleotide phosphate oxidase-induced superoxide 
and the restoration of vascular endothelial nitric oxide synthase 
production. In order to investigate the effects of aliskiren on 
vascular inflammation, leukocyte adhesion assays were con-
ducted in the mechanically-injured mouse femoral artery.65 The 
number of adherent leucocytes was significantly reduced in the 
injured mice treated with aliskiren. Furthermore, aliskiren sig-
nificantly reduced the adhesion of THP-1 (T-helper precursor) 
cells to tumor necrosis factor-alpha-activated human umbilical 
vein endothelial cells and blunted tumor necrosis factor-alpha-
induced renin and Ang II production in these cells. These find-
ings indicate that aliskiren has an anti-inflammatory effect.
Clinical studies
The only available data in humans are those from a recent 
pilot study that evaluated the effects of aliskiren 300 mg daily 
on arterial stiffness and endothelial function in 10 patients 
with uncomplicated Type I diabetes mellitus during clamped 
euglycemia and hyperglycemia. In response to aliskiren, 
the carotid augmentation index decreased during clamped 
euglycemia as did pulse wave velocity during clamped hyper-
glycemia.66 In addition, endothelial-dependent vasodilation 
increased during both clamped euglycemia and hyperglyce-
mia, as did endothelial-independent vasodilation (response 
to sublingual nitroglycerin).
In the ongoing AQUARIUS (Aliskiren Quantitative 
Atherosclerosis Regression Intravascular Ultrasound Study), 
intravascular ultrasonography will be used to assess the 
effects of aliskiren and placebo on atherosclerotic lesions in 
patients with coronary artery disease.
Ongoing studies
Several clinical trials are being carried out to evaluate the 
ability of aliskiren to prevent organ damage and reduce car-
diovascular morbidity and mortality.48,67
In ALTITUDE (Aliskiren Trial In Type 2 Diabetes Using 
Cardio-Renal Endpoints),68 8600 high-risk diabetic patients 
will be randomly given aliskiren 300 mg or placebo in addi-
tion to recommended doses of an ACE-I or ARB in order to 
assess time to first event of a combined renal/cardiovascular 
endpoint which includes cardiovascular death, stroke, myo-
cardial infarction, and hospital admission for heart failure, 
in addition to the development of renal failure or doubling 
of serum creatinine.
ATMOSPHERE (Aliskiren Trial to Minimize Outcomes 
in Patients with Heart Failure) will assess whether aliskiren 
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vascular superoxide and peroxynitrite levels. Furthermore, 
cotreatment with aliskiren and valsartan has additive pro-
tective effects on endothelial function and atherosclerotic 
changes. Histology of the thoracic aorta showed that the 
plaque area was significantly decreased by combination 
therapy compared with monotherapy with either drug.63
In a mouse model of obesity and Type 2 diabetes, Dong 
et al64 demonstrated that both subpressor and hypotensive doses 
of aliskiren significantly reduced cardiac fibrosis, macrophage 
infiltration, and coronary remodeling, and improved vascular Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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delays cardiovascular death or heart failure hospitalization in 
patients with chronic heart failure and systolic dysfunction 
(left ventricular ejection fraction ,40%). Another study, 
ASTRONAUT (Aliskiren Trial on Acute Heart Failure Out-
comes) is evaluating the effect of early initiation of aliskiren 
on death and recurrent hospitalization in the six months fol-
lowing hospital admission for decompensated heart failure. 
Meanwhile, APOLLO (Aliskiren in Prevention Of Later 
Life Outcomes) is assessing the effectiveness of aliskiren-
based therapy in the primary and secondary prevention of 
cardiovascular morbidity and mortality in elderly patients 
with additional risk factors and with or without previous 
cardiovascular events. Finally, the AVANT-GARDE (aliskiren 
and valsartan to reduce NT-proBNP via renin-angiotensin-
aldosterone system blockade) study will assess whether 
aliskiren, alone or in combination with valsartan, improves 
ventricular hemodynamics, as assessed by reductions in NT-
proBNP levels in approximately 1100 patients.
Conclusion
In conclusion, the introduction of aliskiren, a direct renin 
inhibitor, into clinical practice has opened up a new thera-
peutic potential for hypertension and target organ protection. 
Aliskiren monotherapy displays an antihypertensive efficacy 
similar if not superior to that of other first-line antihyperten-
sive drugs, with a safety and tolerability profile comparable 
with that of placebo, and also in special populations, including 
diabetic, obese, and elderly patients. Persistent BP reduction 
and prolonged suppression of PRA are observed after aliskiren 
withdrawal. Combining aliskiren with various antihyperten-
sive agents results in greater antihypertensive efficacy without 
serious adverse drug interactions. Blockade of the RAAS 
obtained with ACEIs or ARBs can be further enhanced by 
adding aliskiren to these drugs. However, although improving 
BP control, the use of such a combination should be tempered 
by the results of ASPIRE, showing an increased incidence of 
adverse events at least in high-risk patients who have had a 
previous myocardial infarction. Data from experimental and 
clinical studies suggest that aliskiren is able to protect against 
end organ damage. The ongoing ASPIRE HIGHER clinical 
trial program, assessing the effects of aliskiren on surrogate 
markers and cardiovascular morbidity and mortality, will 
further define the role of direct renin inhibition in the avail-
able treatment options for hypertension.
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